CMPS vs SLS: Which Stock Is the Better Buy?
COMPASS Pathways plc and SELLAS Life Sciences Group, Inc. side by side — fundamentals from SEC filings, refreshed nightly. Sector: Healthcare.
AI verdict — CMPS vs SLS, read from the filings
The stronger business, the cheaper stock, and the risks — synthesised from both companies’ SEC filings, every figure computed not guessed. Not investment advice.
| COMPASS Pathways plc (CMPS) | SELLAS Life Sciences Group, Inc. (SLS) | |
|---|---|---|
| Market cap | $1.5B | $1.5B |
| Revenue (latest FY) | $0 | $0 |
| Net income (latest FY) | $-287.86M | $-26.86M |
| Revenue growth (5y CAGR) | — | — |
| Net margin | — | — |
| Return on equity | 544.7% | -37.9% |
| P/E ratio | — | — |
| Dividend yield | — | — |
| Profitable years (of last 10) | 0 | 0 |
| Positive free cash flow | — | — |
Verify the comparison
Use the filing period and source shown by each tool before treating two figures as comparable.
See the full CMPS vs SLS breakdown
Both companies across 19 years of income statement, balance sheet and cash flow — with ratios, health checks and Ask, the SEC-grounded research assistant. Free, no account needed.
Open CMPS's full financials → Open SLS's full financials →More comparisons
Frequently asked questions
Which is bigger, CMPS or SLS?
COMPASS Pathways plc is larger by market capitalization — $1.5B versus $1.5B.
Which grows faster, CMPS or SLS?
Five-year growth data is not available for both companies.
Where does this data come from?
All figures are computed from official SEC filings (10-K), refreshed nightly. This is a data comparison, not investment advice.
Keep exploring
CMPS fundamentals → · SLS fundamentals → · All 1,500+ companies → · Free screener →